Use of a Cancer Registry to Evaluate Patient-Reported Outcomes of Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICIs) are increasingly used for advanced lung cancer, but few studies have reported on patient-reported outcomes (PROs) outside the context of a clinical trial. The goal of the current study was to assess PROs in participants of a lung cancer registry who had been treat...
Main Authors: | Heather S. L. Jim, Sarah L. Eisel, Aasha I. Hoogland, Sandra Shaw, Jennifer C. King, Adam P. Dicker |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-12-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/1/103 |
Similar Items
-
Advances on Effects of Triptolide with Non-small Cell Lung Cancer
by: Li WANG, et al.
Published: (2013-07-01) -
The Complex Link between Apoptosis and Autophagy: a Promising New Role for RB
by: JOÃO M.A. DELOU, et al. -
Study on Effects and Mechanisms of Phytochemicals in Vegetables and Fruits
in Preventing and Treating Lung Cancer
by: Tiantian GUO, et al.
Published: (2017-12-01) -
Combination chemotherapy for metastatic colorectal cancer
by: Koehne Claus-Henning
Published: (2003-01-01) -
Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer
by: Di ZHANG, et al.
Published: (2019-06-01)